The AmpliSeq for Illumina BRCA Panel is a targeted resequencing assay for research of somatic and germline variants across BRCA1 and BRCA2 genes. Key features include:
The BRCA Panel is part of an integrated workflow that includes AmpliSeq for Illumina polymerase chain reaction (PCR)-based library preparation, Illumina sequencing by synthesis (SBS) next-generation sequencing (NGS) technology, and automated analysis.
BRCA1 and BRCA2 are human tumor suppressor genes that, when carrying specific mutations, have been implicated in an increased risk for breast and ovarian cancers. This ready-to-use panel saves researchers the time and effort of identifying targets, designing primers, and optimizing panels.
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| iSeq 100 System | 12 samples per run (assumes minimum coverage of 500×) 96 samples per run (assumes minimum coverage of 50x) |
2 × 150 bp 2 × 150 bp |
| MiniSeq System | Samples per run: mid output: 24, high output: 80 (assumes minimum coverage of 500×) | 2 × 150 bp |
| MiSeq System | Samples per run at 500x minimum coverage (by reagent kit version): v2 nano: 3, v2 micro: 12, v2: 48, v3: 80 Samples per run at 50x minimum coverage (by reagent kit version): v2 nano: 32, v2 micro: 96 |
2 × 150 bp 2 × 150 bp |
| AmpliSeq for Illumina BRCA Panel | TruSight Cancer | |
|---|---|---|
| Assay Time | 5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) | 1.5 days |
| Cancer Type | Solid Tumor | Pan-Cancer |
| Content Specifications | Exonic regions and the flanking intronic sequences of the BRCA1 and BRCA2 | Fixed set of probes that enrich for 94 genes and 284 SNPs associated with common and rare cancers. |
| Description | Germline and somatic analysis studies of BRCA1 and BRCA2. | Germline mutation detection research for common and rare cancers. |
| Hands-On Time | < 1.5 hours | 5 hours |
| Input Quantity | 1–100 ng (10 ng recommended per pool) | 50 ng DNA |
| Method | Amplicon Sequencing, Targeted DNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing |
| Multiplexing | 96 dual index combinations | Up to 96-plex |
| Specialized Sample Types | Blood, FFPE Tissue | Not FFPE-Compatible |
| Species Category | Human | Human |
| Variant Class | Germline Variants, Insertions-Deletions (indels), Single Nucleotide Polymorphisms (SNPs), Somatic Variants | Germline Variants |
AmpliSeq for Illumina Oncology Panels on the iSeq 100 System
Application Note | PDF < 1 MB
Automated Solutions for AmpliSeq for Illumina Sequencing Panels
Application Note | HTML
AmpliSeq for Illumina BRCA Panel Data Sheet
Data Sheet | HTML
Sample identification with the AmpliSeq for Illumina Sample ID Panel
Application Note | PDF < 1 MB
Illumina Adapter Sequences Documentation
AmpliSeq for Illumina BRCA Panel Reference Guide Documentation
AmpliSeq for Illumina Direct FFPE DNA Kit Reference Guide Documentation
AmpliSeq for Illumina BRCA Panel Consumables & Equipment Documentation
AmpliSeq for Illumina BRCA Panel Checklist Documentation
AmpliSeq for Illumina Custom and Community Panels Documentation
AmpliSeq for Illumina BRCA Panel Documentation
Index Adapters Pooling Guide Documentation
Custom Protocol Selector
Generates customized, end-to-end instructions
Targeted DNA and RNA research panel investigating variants across 161 genes associated with a range of cancer types.
Targeted research panel investigating hotspot regions of 50 genes with known associations to cancer.
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
Targeted panel that measures expression levels of >20,000 human RefSeq genes.
These expert-defined sequencing research panels target 94 genes and 284 SNPs associated with a predisposition towards various cancers.
These sequencing reagent kits offer increased stability and robustness over the v2 kit version.
